(object) array( 'id' => '3898056', 'url' => 'FR/variable_ratio_₁', 'image' => '', 'title' => 'Proportion variable', 'tags' => array ( 0 => 'Proportion variable', 1 => 'Pharmaceutical', 2 => 'Pharmaceutical intermediates', 3 => '', ), 'term' => 'Proportion variable', 'source_id' => 3744260, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Pharmaceutical intermediates', ), 'lastedit' => '20150722105908', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => '1) Un programme de renforcement basé sur la réponse dans lequel le nombre de réponses requises pour un renforcement varie après que chaque renforçateur est présenté. Le nombre moyen de réponses est utilisé pour indexer le programme. Par exemple, un rat peut appuyer sur un levier de renforcement 50 fois, puis 150, 70, 30, et 200. En ajoutant ces besoins de réponse pour un total de 500, puis en divisant par le nombre de réponses distinctes apportées (5), on obtient la valeur du programme, PV 100. 2) Un programme dans lequel une personne est renforcée en effectuant une réponse seulement après avoir effectué un nombre variable de ces réponses sans renforcement. Ce programme induit généralement un rythme élevé et uniforme. Il produit le plus haut rythme de réponses pour les programmes simples.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851744059393, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => '1) A response-based schedule of reinforcement in which the number of responses required for reinforcement changes after each reinforcer is presented. The average number of responses is used to index the schedule. For example, a rat may press a lever for reinforcement 50 times, then 150, 70, 30, and 200. Adding these response requirements for a total of 500, then dividing by the number of separate response runs (5), yields the schedule value, VR 100. 2) A schedule in which people are reinforced for making a response only after they have made a varying number of those responses without reinforcement. This schedule usually causes people to work at a high and uniform rate of speed. It produces the highest rate of responding of the simple schedules.', 'Domain' => 'Documentation', 'Industry' => 'Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Pharmaceutical intermediates', 'See Also' => 'ratio schedules of reinforcement_₀', 'Usage Status' => 'New', 'Creation User' => 'lovinbnsingle', 'Creation Date' => '2012/9/5', 'Glossary' => 'MODULE_3_twgid1346807673617222', 'Term' => 'variable ratio', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'variable_ratio_₁', )

(object) array( 'id' => '3951142', 'url' => 'FR/Yawning-No-More', 'image' => 'yawning.jpg; bush yawning.jpg;', 'title' => 'Yawning-No-More', 'tags' => array ( 0 => 'Yawning-No-More', 1 => 'Pharmaceutical', 2 => 'Drugs', 3 => '', ), 'term' => 'Yawning-No-More', 'source_id' => 639288, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Drugs', ), 'lastedit' => '20150721084108', 'part_of_speech' => 'proper noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un nouveau médicament de relaxation musculaire qui stoppe les bâillements pendant un certain nombre d\'heures. Le bâillement est une réaction allergique du corps à cause de la fatigue, du manque de stimulation, ou de l\'ennui. Yawning-No-More détend les muscles qui induisent le bâillement ainsi la personne peut éviter de bâiller jusqu\'à cinq heures. Le bâillement peut être gênant lors de rassemblements sociaux ou des réunions d\'affaires car il peut montrer un manque d\'intérêt ou d\'énergie. Ce nouveau médicament promet de changer sensiblement la façon dont la société voit le bâillement.', 'usage_comment' => '', 'glossary' => '', 'width' => 503, 'height' => 340, '_version_' => 1507294573051772928, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'Yawning-No-More', 'Definition' => 'A new muscle relaxation drug that stops yawning for a number of hours. Yawing is an allergic reaction of the body due to tiredness, lack of stimulation, or boredom. Yawning-No-More relaxes the muscles that induce yawning so the person can be spared of yawning for up to five hours. Yawning can be embarrassing during social gatherings or business meetings as it may show a lack of interests or energy. This new drug promises to substantially change the way society views yawning.', 'Part of Speech' => 'proper noun', 'Usage Status' => 'New', 'Sample Image' => 'yawning.jpg; bush yawning.jpg;', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Drugs', 'Creation User' => 'BruceLH', 'Creation Date' => '2011/1/23', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'Yawning-No-More', )

(object) array( 'id' => '7745840', 'url' => 'FR/experimental_treatment', 'image' => '', 'title' => 'Traitement expérimental', 'tags' => array ( 0 => 'Traitement expérimental', 1 => 'Pharmaceutical', 2 => 'Clinical trials', 3 => '', ), 'term' => 'Traitement expérimental', 'source_id' => 1259724, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'lastedit' => '20150721084114', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Le nouveau médicament ou thérapie testé dans l\'essai clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507294573052821507, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'experimental treatment', 'Definition' => 'The new drug or therapy being tested in the clinical trial.', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Clinical trials', 'Creation User' => 'John Martin', 'Creation Date' => '2011/5/16', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'experimental_treatment', )

(object) array( 'id' => '10479591', 'url' => 'FR/actinic_keratoses_₂', 'image' => '', 'title' => 'Kératose actinique', 'tags' => array ( 0 => 'Kératose actinique', 1 => 'Beauty', 2 => 'Skin care', 3 => '', ), 'term' => 'Kératose actinique', 'source_id' => 5092398, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Beauty', ), 'category' => array ( 0 => 'Skin care', ), 'lastedit' => '20150728083418', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Lésions précancéreuses se traduisant par une zone rouge, épaisse et rugueuse ; elles apparaissent habituellement sur une peau endommagée par le soleil.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507928310838984706, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => 'Precancerous growths that can appear red, thick, and rough; usually found on sun-damaged skin.', 'Part of Speech' => 'noun', 'Industry' => 'Beauty', 'Product Category' => 'Skin care', 'Creation User' => 'MaryK', 'Creation Date' => '2013/3/15', 'Term' => 'actinic keratoses', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'actinic_keratoses_₂', )

(object) array( 'id' => '7745839', 'url' => 'FR/investigational_treatment', 'image' => '', 'title' => 'Traitement expérimental', 'tags' => array ( 0 => 'Traitement expérimental', 1 => 'Pharmaceutical', 2 => 'Clinical trials', 3 => '', ), 'term' => 'Traitement expérimental', 'source_id' => 1259723, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'lastedit' => '20150721084114', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Le nouveau médicament ou thérapie testé dans l\'essai clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507294573052821506, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'investigational treatment', 'Definition' => 'The new drug or therapy being tested in the clinical trial.', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Synonym' => 'experimental_treatment', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Clinical trials', 'Creation User' => 'John Martin', 'Creation Date' => '2011/5/16', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'investigational_treatment', )

(object) array( 'id' => '6227397', 'url' => 'FR/exclusion_criteria_₁', 'image' => '', 'title' => 'Critères d\'exclusion', 'tags' => array ( 0 => 'Critères d\'exclusion', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Critères d\'exclusion', 'source_id' => 4010892, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150722105910', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Les facteurs ou les raisons qui empêchent une personne de participer à une étude clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507393851744059394, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'The factors or reasons that prevent a person from participating in a clinical study.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'exclusion criteria', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'exclusion_criteria_₁', )

(object) array( 'id' => '7745836', 'url' => 'FR/informed_consent_₇', 'image' => '', 'title' => 'Consentement éclairé', 'tags' => array ( 0 => 'Consentement éclairé', 1 => 'Pharmaceutical', 2 => 'Clinical trials', 3 => '', ), 'term' => 'Consentement éclairé', 'source_id' => 1259720, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'lastedit' => '20150721084111', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Un processus afin de s\'assurer que les patients volontaires comprennent tous les risques associés à la participation à un essai clinique tels que les effets indésirables et choisissent de participer sans coercition ni pression de quiconque. Le chercheur principal ou de ses associés sont tenus d\'expliquer l\'étude attentivement et répondre à toutes les questions d\'un participant avant l\'essai clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507294573052821505, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Term' => 'informed consent', 'Definition' => 'A process to ensure that patient volunteers understand all the risks associated participating in a clinical trial such as adverse side effects and are choosing to participate without coercion or pressure from anyone. The principal investigator or his or her associates are required to explain the study carefully and answer all questions of a participant before the clinical trial.', 'Part of Speech' => 'noun', 'Usage Status' => 'New', 'Industry' => 'Pharmaceutical', 'Product Category' => 'Clinical trials', 'Creation User' => 'John Martin', 'Creation Date' => '2011/5/16', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'informed_consent_₇', )

(object) array( 'id' => '6228625', 'url' => 'FR/publications_₂', 'image' => '', 'title' => 'Publications', 'tags' => array ( 0 => 'Publications', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Publications', 'source_id' => 4011325, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150722110603', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Articles ou résumés scientifiques publiés concernant une étude clinique.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507394292251885568, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'Published scientific articles or abstracts about a clinical study.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'publications', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'publications_₂', )

(object) array( 'id' => '10479590', 'url' => 'FR/acne_vulgaris_₂', 'image' => '', 'title' => 'Acné vulgaire', 'tags' => array ( 0 => 'Acné vulgaire', 1 => 'Beauty', 2 => 'Skin care', 3 => '', ), 'term' => 'Acné vulgaire', 'source_id' => 5092397, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Beauty', ), 'category' => array ( 0 => 'Skin care', ), 'lastedit' => '20150728083415', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Le type d\'acné le plus commun, caractérisé par des points noirs, des points blancs, des papules et des pustules, communément appelé boutons.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507928310838984705, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Definition' => 'The most common type of acne, associated with blackheads, whiteheads, papules, and pustules, commonly referred to as pimples or zits.', 'Part of Speech' => 'noun', 'Industry' => 'Beauty', 'Product Category' => 'Skin care', 'Creation User' => 'MaryK', 'Creation Date' => '2013/3/15', 'Term' => 'acne vulgaris', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'acne_vulgaris_₂', )

(object) array( 'id' => '6228620', 'url' => 'FR/primary_outcome_measure', 'image' => '', 'title' => 'Critère de jugement principal', 'tags' => array ( 0 => 'Critère de jugement principal', 1 => 'Medical devices', 2 => 'Pharmaceutical', 3 => 'Clinical trials', 4 => 'National Library of Medicine', 5 => '', ), 'term' => 'Critère de jugement principal', 'source_id' => 4011188, 'type' => 'term', 'namespace' => 1244, 'nstext' => 'FR', 'industry' => array ( 0 => 'Medical devices', 1 => 'Pharmaceutical', ), 'category' => array ( 0 => 'Clinical trials', ), 'company' => array ( 0 => 'National Library of Medicine', ), 'lastedit' => '20150727104701', 'part_of_speech' => 'noun', 'creation_user' => 'LinguaDiligence', 'special_term' => '', 'definition' => 'Le critère de jugement défini dans le protocole qui est le plus important pour évaluer l\'effet d\'une intervention. La plupart des études cliniques ont un critère de jugement principal, mais certaines peuvent en avoir plusieurs.', 'usage_comment' => '', 'glossary' => '', 'width' => 0, 'height' => 0, '_version_' => 1507846081752334336, 'nstext_full' => 'French (FR)', 's_attr' => (object) array( 'Company' => 'National Library of Medicine', 'Definition' => 'The planned outcome measure in the protocol that is the most important for evaluating the effect of an intervention. Most clinical studies have one primary outcome measure, but some may have more than one.', 'Industry' => 'Medical devices; Pharmaceutical', 'Part of Speech' => 'noun', 'Product Category' => 'Clinical trials', 'Creation User' => 'elighy', 'Creation Date' => '2012/10/13', 'Term' => 'primary outcome measure', 'Source Lang' => '1180', ), 's_namespace_text' => 'EN', 's_namespace_text_full' => 'English (EN)', 's_title' => 'primary_outcome_measure', )